A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France

The aim of this study was to assess which cytoreductive treatments are currently administered in standard practice as second-line therapy to patients with polycythemia vera (PV) in France and to find out the reasons physicians switch treatments. In addition, the research aimed to describe real-world effectiveness of second-line cytoreductive therapies and the occurrence of adverse events of special interest. Study data were collected from the medical charts of patients who initiated a second-line cytoreductive agent for the treatment of PV and received their first dose between 1 Jan 2022 and 31 Dec 2023.

Sex

All

Minimum age

18 Years

Maximum age

99 Years

Inclusion criteria:

1. Male or female patient diagnosed with PV after 01 Jan 2014 according to World Health Organization (WHO) criteria.
2. Patient ≥ 18 years of age at the time of PV diagnosis.
3. Patient who received a first dose of a second-line cytoreductive treatment between 01 Jan 2022 and 31 Dec 2023.

Exclusion criteria:

1. Patient alive at study initiation who opposed to data use for research purposes.
2. Patient who died before study initiation and who had opposed to data use for research purpose prior to their death.
3. Patient who took part in an interventional clinical trial(s) between 01 January 2022 and 31 December 2023.